Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2017

01-04-2017 | Review

Dysbiosis a risk factor for celiac disease

Authors: Anamaria Girbovan, Genel Sur, Gabriel Samasca, Iulia Lupan

Published in: Medical Microbiology and Immunology | Issue 2/2017

Login to get access

Abstract

Celiac disease remains one of the most challenging pathologies of the small intestine. It involves multiple pathogenic pathways and there are no disease-changing pharmacological agents available against it yet. The term microbiota refers to the community of microorganisms that inhabit a particular region of the body. Normal gut microbiota has a vital role in maintaining the intestinal homeostasis and promoting health. Celiac disease is associated with microbiota alteration, especially with an increase in the number of Gram-negative bacteria and a decrease in the number of Gram-positive bacteria. There is a strong relationship between intestinal dysbiosis and celiac disease, and recent studies are aimed at determining whether the celiac disease is a risk factor for dysbiosis or dysbiosis is for celiac disease. Therefore, the aim of this review was to assess the latest findings regarding the gut microbiota and its impact on the celiac disease, including therapeutic aspects.
Literature
1.
Bai JC, Fried M, Corazza GR et al (2013) World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol 47:121–126CrossRefPubMed
2.
Frank DN, St Amand AL, Feldman RA et al (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780–13785CrossRefPubMedPubMedCentral
3.
4.
5.
De Palma G, Capilla A, Nadal I et al (2010) Interplay between human leukocyte antigen genes and the microbial colonization process of the newborn intestine. Curr Issues Mol Biol 12:1–10PubMed
6.
Palma GD, Capilla A, Nova E et al (2012) Influence of milk-feeding type and genetic risk of developing coeliac disease on intestinal microbiota of infants: the PROFICEL study. PloS One 7:e30791CrossRefPubMedPubMedCentral
7.
Olivares M, Laparra JM, Sanz Y (2013) Host genotype, intestinal microbiota and inflammatory disorders. Br J Nutr 109:S76–S80CrossRefPubMed
8.
Olivares M, Neef A, Castillejo G et al (2015) The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut 64:406–417CrossRefPubMed
9.
Kupfer S, Jabri B (2012) Pathophysiology of celiac disease. Gastrointest Endosc Clin N Am 22:639–660CrossRefPubMed
10.
11.
Garrote JA, Gómez-González E, Bernardo D et al (2008) Celiac disease pathogenesis: the proinflammatory cytokine network. J Pediatr Gastroenterol Nutr 47:S27–S32CrossRefPubMed
12.
13.
Icaza-Chavez ME (2013) Gut microbiota in health and disease. Rev Gastroenterol Mex 78:240–248PubMed
14.
Bustos Fernandez LM, Lasa JS et al (2014) Intestinal microbiota: its role in digestive diseases. J Clin Gastroenterol 48:657–666CrossRefPubMed
15.
McLean MH, Dieguez D Jr, Miller LM et al (2015) Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut 64:332–341CrossRefPubMed
16.
Carding S, Verbeke K, Vipond DT et al (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26:26191PubMed
17.
Ou G, Hedberg M, Horstedt P, Baranov V et al (2009) Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol 104:3058–3067CrossRefPubMed
18.
Cinova J, De Palma G, Stepankova R et al (2011) Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PloS One 6:e16169CrossRefPubMedPubMedCentral
19.
Kalliomaki M, Satokari R, Lahteenoja H et al (2012) Expression of microbiota, Toll-like receptors, and their regulators in the small intestinal mucosa in celiac disease. J Pediatr Gastroenterol Nutr 54:727–732CrossRefPubMed
20.
Cheng J, Kalliomaki M, Heilig HG et al (2013) Duodenal microbiota composition and mucosal homeostasis in pediatric celiac disease. BMC Gastroenterol 13:113CrossRefPubMedPubMedCentral
21.
De Palma G, Kamanova J, Cinova J et al (2012) Modulation of phenotypic and functional maturation of dendritic cells by intestinal bacteria and gliadin: relevance for celiac disease. J Leukoc Biol 92:1043–1054CrossRefPubMed
22.
Sjoberg V, Sandstrom O, Hedberg M et al (2013) Intestinal T-cell responses in celiac disease - impact of celiac disease associated bacteria. PloS One 8:e53414CrossRefPubMedPubMedCentral
23.
Hawrelak J, Myers S (2004) The causes of intestinal dysbiosis: a review. Altern Med Rev 9:180–197PubMed
24.
Marild K, Ye W, Lebwohl B et al (2013) Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol 13:109CrossRefPubMedPubMedCentral
25.
Galipeau HJ, McCarville JL, Huebener S et al (2015) Intestinal microbiota modulates gluten-induced immunopathology in humanized mice. Am J Pathol 185:2969–2982CrossRefPubMedPubMedCentral
26.
27.
Caminero A, Galipeau HJ, McCarville JL et al (2016) Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology 151:670–683CrossRefPubMed
28.
Moran C, Sheehan D, Shanahan F (2015) The small bowel microbiota. Curr Opin Gastroenterol 31:130–136CrossRefPubMed
29.
Cenit MC, Olivares M, Codoner-Franch P et al (2015) Intestinal microbiota and celiac disease: cause, consequence or co-evolution? Nutrients 7:6900–6923CrossRefPubMedPubMedCentral
30.
Sánchez E, Nadal I, Donat E et al (2008) Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children. BMC Gastroenterol 8:50CrossRefPubMedPubMedCentral
31.
Sanchez E, Ribes-Koninckx C, Calabuig M et al (2012) Intestinal Staphylococcus spp. and virulent features associated with coeliac disease. J Clin Pathol 65:830–834CrossRefPubMed
32.
Collado MC, Donat E, Ribes-Koninckx C et al (2009) Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol 62:264–269CrossRefPubMed
33.
34.
Di Cagno R, De Angelis M, De Pasquale I et al (2011) Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 11:219CrossRefPubMedPubMedCentral
35.
Sanchez E, Donat E, Ribes-Koninckx C et al (2013) Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol 79:5472–5479CrossRefPubMedPubMedCentral
36.
Francavilla R, Ercolini D, Piccolo M et al (2014) Salivary microbiota and metabolome associated with celiac disease. Appl Environ Microbiol 80:3416–3425CrossRefPubMedPubMedCentral
37.
Giron Fernandez-Crehuet F, Tapia-Paniagua S, Morinigo Gutierrez MA et al (2016) The duodenal microbiota composition in children with active coeliac disease is influenced by the degree of enteropathy. An Pediatr (Barc) 84:224–230CrossRef
38.
D’Argenio V, Casaburi G, Precone V et al (2016) Metagenomics reveals dysbiosis and a potentially pathogenic N. flavescens strain in duodenum of adult celiac patients. Am J Gastroenterol 111:879–890CrossRefPubMedPubMedCentral
39.
Nistal E, Caminero A, Herran AR et al (2012) Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 18:649–656CrossRefPubMed
40.
41.
Nistal E, Caminero A, Vivas S et al (2012) Differences in faecal bacteria populations and faecal bacteria metabolism in healthy adults and celiac disease patients. Biochimie 94:1724–1729CrossRefPubMed
42.
Golfetto L, de Senna FD, Hermes J et al (2014) Lower bifidobacteria counts in adult patients with celiac disease on a gluten-free diet. Arq Gastroenterol 51:139–143CrossRefPubMed
43.
Wacklin P, Laurikka P, Lindfors K et al (2014) Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol 109:1933–1941CrossRefPubMed
44.
Wacklin P, Kaukinen K, Tuovinen E, et al (2013) The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis 2013;19:934–941CrossRefPubMed
45.
46.
Pozo-Rubio TG, Mujico JR, Olivares M et al (2013) Influence of early environmental factors on lymphocyte subsets and gut microbiota in infants at risk of celiac disease; the PROFICEL study. Nutr Hosp 28:464–473PubMed
47.
48.
Gerald Friedman (2012) Clinical applications of probiotics in gastroenterology: questions and answers, an issue of gastroenterology clinics. Saunders, United States
49.
Fons M, Gomez A (2000) Mechanisms of colonisation and colonisation resistance of the digestive tract. Microbial Ecol Health Dis 12:240–246CrossRef
50.
Hardy H, Harris J, Lyon E et al (2013) Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 5:1869–1912CrossRefPubMedPubMedCentral
51.
Sherman PM, Ossa JC, Johnson-Henry K (2009) Unraveling mechanisms of action of probiotics. Nutr Clin Pract 24:10–14CrossRefPubMed
52.
Iebba V, Santangelo F, Totino V et al (2013) Higher prevalence and abundance of Bdellovibrio bacteriovorus in the human gut of healthy subjects. PloS One 8:e61608CrossRefPubMedPubMedCentral
53.
De Sousa Moraes LF, Grzeskowiak LM, de Sales Teixeira TF et al (2014) Intestinal microbiota and probiotics in celiac disease. Clin Microbiol Rev 27:482–489CrossRef
54.
Olivares M, Castillejo G, Varea V et al (2014) Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br J Nutr 112:30–40CrossRefPubMed
55.
Lorenzo Pisarello MJ, Vintini EO, Gonzalez SN et al (2015) Decrease in lactobacilli in the intestinal microbiota of celiac children with a gluten-free diet, and selection of potentially probiotic strains. Can J Microbiol 61:32–37CrossRefPubMed
56.
Klemenak M, Dolinsek J, Langerholc T et al (2015) Administration of bifidobacterium breve decreases the production of TNF-alpha in children with celiac disease. Dig Dis Sci 60:3386–3392CrossRefPubMed
57.
Wei G, Tian N, Valery AC et al (2015) Identification of pseudolysin (lasB) as an aciduric gluten-degrading enzyme with high therapeutic potential for celiac disease. Am J Gastroenterol 110:899–908CrossRefPubMedPubMedCentral
58.
Mohammadi R, Hosseini-Safa A, Ehsani Ardakani MJ et al (2015) The relationship between intestinal parasites and some immune-mediated intestinal conditions. Gastroenterol Hepatol Bed Bench 8:123–131PubMedPubMedCentral
59.
Croese J, Giacomin P, Navarro S et al (2015) Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol 135:508–516CrossRefPubMed
60.
Giacomin P, Zakrzewski M, Croese J et al (2015) Experimental hookworm infection and escalating gluten challenges are associated with increased microbial richness in celiac subjects. Sci Rep 5:13797CrossRefPubMedPubMedCentral
61.
Kverka M, Tlaskalova-Hogenova H (2013) Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs. APMIS 121:403–421CrossRefPubMed
62.
Conlon AM, Bird AR (2015) The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7:17–44CrossRef
63.
De Angelis M, Vannini L, Di Cagno R et al (2016) Salivary and fecal microbiota and metabolome of celiac children under gluten-free diet. Int J Food Microbiol 19(239):125–132CrossRef
Metadata
Title
Dysbiosis a risk factor for celiac disease
Authors
Anamaria Girbovan
Genel Sur
Gabriel Samasca
Iulia Lupan
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2017
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-017-0496-z

Other articles of this Issue 2/2017

Medical Microbiology and Immunology 2/2017 Go to the issue

Original Investigation

iTRAQ-based quantitative proteomics reveals important host factors involved in the high pathogenicity of the H5N1 avian influenza virus in mice

Original Investigation

MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients

Rapid Communication

Development of a high-throughput colorimetric Zika virus infection assay

Original Investigation

Paracoccidioides brasiliensis induces cytokine secretion in epithelial cells in a protease-activated receptor-dependent (PAR) manner

Original Investigation

Using dendritic cells to evaluate how Burkholderia cenocepacia clonal isolates from a chronically infected cystic fibrosis patient subvert immune functions

Original Investigation

Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits